Gouty Arthritis (Gout) - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2017, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gouty Arthritis (Gout) - Overview
Gouty Arthritis (Gout) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gouty Arthritis (Gout) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
AstraZeneca Plc
C&C Research Laboratories
Cell Medica Ltd
CymaBay Therapeutics Inc
Genentech Inc
Immune Response BioPharma Inc
Jiangsu Hengrui Medicine Co Ltd
Monosol Rx LLC
Opsona Therapeutics Ltd
Polaris Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Teijin Pharma Ltd
Wellstat Therapeutics Corp
XL-protein GmbH
Gouty Arthritis (Gout) - Drug Profiles
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arhalofenate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colchicine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapansutrile - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSA-Uricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-191 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REV-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLBN-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Gout - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URC-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uriSHELS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WT-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gouty Arthritis (Gout) - Dormant Projects
Gouty Arthritis (Gout) - Discontinued Products
Gouty Arthritis (Gout) - Product Development Milestones
Featured News & Press Releases
Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Nov 13, 2016: Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout
Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology
Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H1 2017
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2017
Gouty Arthritis (Gout) - Pipeline by Cell Medica Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H1 2017
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H1 2017
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Gouty Arthritis (Gout) - Discontinued Products, H1 2017